TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01452243
Drug: Vitamin D and calcium suplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
Study: NCT00548678
Drug: intravenous diclofenac sodium (DIC075V)
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous diclofenac sodium
Study: NCT00548678
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous ketorolac
Study: NCT00548678
Drug: oral diclofenac (Cataflam)
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral diclofenac (Cataflam)
Study: NCT02065609
Drug: HER2 Positive Lesion Detection and Safety
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
Study: NCT01452880
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
Study: NCT01452880
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
Study: NCT00435331
Drug: sapropterin dihydrochloride (6R-BH4)
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
Study: NCT01467713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon sublingual (SL) placebo-matching tablets
Study: NCT02832687
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
Study: NCT02832687
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL of normal saline every 4 hours to a maximum administration of 400mL
Study: NCT01593774
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet melatonin 3 mg/day at 9 pm as intervention group
Study: NCT01593774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with the same shape and taste as melatonin) at 9 pm as control group
Study: NCT02019472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections
Study: NCT01563042
Drug: Intravenous (IV) single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2434735 administered as a single intervenous dose at the beginning of the study
Study: NCT01563042
Drug: Subcutaneous (SC) single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2434735 administered as a single subcutaneous dose at the beginning of the study
Study: NCT02974686
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03283566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
Study: NCT00818766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
Study: NCT01178372
Drug: Probiotics(VSL#3)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive VSL#3 (110 billion CFU)three times a day
Study: NCT02568306
Drug: NNC0165-1562
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
Study: NCT02568306
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
Study: NCT01861015
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02845024
Drug: Doxycycline Group
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxycycline 100mg was taken within 15 days
Study: NCT02845024
Drug: placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo was taken within 15 days
Study: NCT00853008
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
Study: NCT00853008
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
Study: NCT00853008
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
Study: NCT01296087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule given once daily on Days 1 to 28
Study: NCT01125189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, 0 mg, once daily, 24 weeks
Study: NCT01343043
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.
Study: NCT03693131
Drug: Icosapent (MND-2119)
DrugBank: Icosapent (DB00159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icosapent (MND-2119) capsules.
Study: NCT03693131
Drug: Icosapent (EPADEL CAPSULES 300)
Normalized name: Icosapent Ethyl Capsules
DrugBank: Icosapent (DB00159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icosapent (EPADEL CAPSULES 300) capsules.
Study: NCT04248868
Drug: r-tPA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse spray and infusion
Study: NCT01496677
Drug: TR-701 FA 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral tablet of TR-701 FA to elderly subjects
Study: NCT02562989
Drug: [18F]MK-6240, ~185 MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of \~185 MBq \[18F\]MK-6240
Study: NCT02562989
Drug: [18F]MK-6240, ~160 MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of \~160 MBq \[18F\]MK-6240
Study: NCT00976729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00128882
Drug: Anti-D
Normalized name: D-Gam Anti-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT04756882
Drug: AbobotulinumtoxinA 500 UNT
Normalized name: abobotulinumtoxinA 500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes
Study: NCT00428246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02271334
Drug: Proventil® MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 90 mcg, 2 inhalations
Study: NCT03191383
Drug: Placebo (Formulation buffer S9b)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study: NCT00766012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
Study: NCT00299325
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT03442751
Drug: Test Article A
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin Ophthalmic Solution A
Study: NCT03442751
Drug: Test Article B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin Ophthalmic Solution B
Study: NCT03442751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Vehicle of Test Article
Study: NCT01946620
Drug: Flutiform
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05468294
Drug: F16IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
Study: NCT02179892
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
Study: NCT02179892
Drug: Oral Acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 650 mg every 6 hours.
Study: NCT02159131
Drug: GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
Study: NCT03631446
Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination powder for oral solution
Study: NCT01332344
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: asthma subjects newly prescribed inhaled corticosteroids in clinical practice
Study: NCT00660517
Drug: MP29-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
Study: NCT00660517
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray one spray per nostril two times a day
Study: NCT00519116
Drug: Rapamune® (Sirolimus)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04299880
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04299880
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT00526630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given placebo instead of active MPD.
Study: NCT02123264
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid: 5 mg/year x 2 years
Study: NCT01935141
Drug: Visipaque 320 non-ionic isoosmolar contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.
Study: NCT01422213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules; daily; orally
Study: NCT01972776
Drug: QBM076
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in 25 mg and 75 mg capsules
Study: NCT04146441
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX Regime according to Norwegian national guidelines
Study: NCT01862978
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01862978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01087125
Drug: No Interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Interventions
Study: NCT01355588
Drug: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
Study: NCT01355588
Drug: Ketorolac Tromethamine with 5% Lidocaine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
Study: NCT01355588
Drug: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
Study: NCT01972776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT01757587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg 2 tablets / day on 3 months, both periods of treatment
Study: NCT00501462
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 250 mg dose of drug
Study: NCT00537680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
Study: NCT00179517
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02858804
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2, IV, d1-4
Study: NCT02858804
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 ,d5
Study: NCT04398004
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 500 mg Clarithromycin orally twice daily for seven days
Study: NCT01555749
Drug: NNC172-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
Study: NCT01555749
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection administered subcutaneously (s.c., under the skin)
Study: NCT02630251
Drug: GSK2820151
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
Study: NCT02731430
Drug: intrathecal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Study: NCT04000139
Drug: Standardized anthocyanin-rich extract
Normalized name: Vitis vinifera anthocyanins extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Study: NCT04000139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Study: NCT02174627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Study: NCT03481972
Drug: Doxycycline and tauroursodeoxycholic acid
Normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycicline and tauroursodeoxycholic acid
Study: NCT03858972
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reduced dose of capecitabine
Study: NCT02935712
Drug: AZD8601+Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
Study: NCT02935712
Drug: Placebo+Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to receive 2 placebo treatments.
Study: NCT01938638
Drug: BAY1143572
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01537042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period.
Study: NCT02473627
Drug: DS-1971a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg tablet
Study: NCT02473627
Drug: Buproprion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg Prolonged release tablet
Study: NCT00413582
Drug: Patient-Controlled IV Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
Study: NCT00019773
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01804946
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficiency of Ergoferon in treatment of Influenza
Study: NCT00315458
Drug: Placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match buprenorphine transdermal patch 10 or 20.
Study: NCT02433184
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
Study: NCT02433184
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
Study: NCT00147875
Drug: Doxorubicin (Adriamycin)
Normalized name: doxorubicin Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00722137
Drug: Cyclophosphamide 750 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study: NCT00722137
Drug: Doxorubicin 50 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Study: NCT00722137
Drug: VELCADE 1.3 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
Study: NCT02822937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT00333827
Drug: optimal therapy for cardiaca failure
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal therapy for cardiaca failure
Study: NCT01006304
Drug: JNJ-39439335, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02913118
Drug: Fluoroquinolones
Normalized name: Fluoroquinolones
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02913118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02553018
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00733421
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg once daily
Study: NCT04344483
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
Study: NCT00075205
Drug: SR141716 (Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04239755
Drug: Doxycycline 100 MG Oral Tablet
Normalized name: DOXYCYCLINE 100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
Study: NCT01441024
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg per day of DAS181-FO3 for 5 days
Study: NCT00191581
Drug: Human Insulin Mix 50:50
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01217112
Drug: GWP42003
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg capsules, PO, BD, 91 days
Study: NCT01217112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg capsules, QDS, PO, 91 days
Study: NCT02596971
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Study: NCT02596971
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Study: NCT04671420
Drug: Mabthera®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.